Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session


  • Crown ElectroKinetics Corp. CRKN shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
  • First Citizens BancShares, Inc. FCNCA shares surged 42.5% to $829.82 after First-Citizens Bank & Trust Company entered an agreement to purchase all deposits and loans of Silicon Valley Bank.
  • Alpine Acquisition Corporation REVE surged 32% to $14.17.
  • Coeptis Therapeutics Holdings, Inc. COEP shares jumped 30% to $1.93 after gaining 8% on Friday.
  • Jounce Therapeutics, Inc. JNCE gained 23% to $1.86. Jounce Therapeutics entered into agreement to be acquired by Concentra Biosciences for $1.85 in cash per share plus contingent value rights.
  • Silvergate Capital Corporation SI gained 21.5% to $2.09. Silvergate Capital shares jumped 52% on Friday as traders circulated a rumor that a crypto exchange is trying to buy the company's trade processing technologies.
  • Cimpress plc CMPR jumped 21.4% to $37.91. Truist Securities maintained Cimpress with a Buy and raised the price target from $45 to $50.
  • Gorilla Technology Group Inc. GRRR surged 20.5% to $9.81.
  • Pyxis Oncology, Inc. PYXS gained 20.4% to $2.66. Pyxis Oncology recently reported loss of $3.65 per share in FY22.
  • Cyclerion Therapeutics, Inc. CYCN rose 20.2% to $0.5248. Cyclerion Therapeutics received US FDA orphan drug designation for Zagociguat for treatment of mitochondrial diseases.
  • FG Financial Group, Inc. FGF rose 20% to $2.58 after posting a narrower quarterly loss.
  • Delcath Systems, Inc. DCTH gained 19.8% to $5.80 after reporting Q4 results. The FDA has accepted the company’s New Drug Application resubmission for HEPZATO Kit (melphalan hydrochloride for injection/hepatic delivery system) seeking approval for unresectable hepatic-dominant metastatic ocular melanoma.
  • Berkshire Grey, Inc. BGRY jumped 19.4% to $1.3606 as the company entered into definitive merger agreement with SoftBank Group for a go-private transaction.
  • Loop Industries, Inc. LOOP gained 17.9% to $2.24.
  • First Republic Bank FRC shares climbed 15.9% to $14.32 in sympathy with Silicon Valley Bank after First Citizens BancShares announced it will purchase all loans and certain other assets of SVB.
  • Brainstorm Cell Therapeutics Inc. BCLI gained 12.9% to $1.75. The FDA will hold an Advisory Committee meeting to discuss the company’s application for NurOwn for amyotrophic lateral sclerosis.
  • Blackbaud, Inc. BLKB gained 12.9% to $65.32 over reports of a possible takeover offer. However, after reviewing the offer, Blackbaud's board rejected the non-binding proposal from Clearlake Capital Group, L.P., to acquire all of the company's outstanding shares for $71.00 per share in cash.
  • Iovance Biotherapeutics, Inc. IOVA shares rose 11.7% to $6.18. Iovance Biotherapeutics completed Biologics License Application submission for Lifileucel in advanced melanoma.
  • Roku, Inc. ROKU gained 8.6% to $65.17. Susquehanna upgraded Roku from Neutral to Positive and announced a $75 price target.
  • Harrow Health, Inc. HROW climbed 7.8% to $19.87. The company recently posted upbeat quarterly earnings.
  • CytomX Therapeutics, Inc. CTMX rose 7.1% to $1.82. CytomX Therapeutics is expected to report full year 2022 financial results on Monday, March 27, 2023, after the closing bell.
  • Novartis AG NVS surged 7% to $89.42 after the company announced positive results from a trial of its breast cancer treatment.
  • KeyCorp KEY climbed 5% to $12.44. Citigroup upgraded KeyCorp from Neutral to Buy and announced a $20 price target.


  • Unity Biotechnology, Inc. UBX shares dipped 46.3% to $2.23 after the company said its phase 2 ENVISION study did not meet its non-inferiority threshold due to strength in the control group.
  • Near Intelligence, Inc. NIR shares tumbled 25.5% to $9.07.
  • Pharming Group N.V. PHAR fell 18.9% to $12.31. The FDA approved Pharming Group’s Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
  • Virios Therapeutics, Inc. VIRI fell 12.4% to $0.3899 after jumping around 44% on Friday.
  • Bird Global, Inc. BRDS fell 11.2% to $0.1331 after gaining over 5% on Friday.
  • YS Biopharma Co., Ltd. YS dropped 10.6% to $4.2819 after the company reported interim Phase 2 safety and immunogenicity data for its PIKA recombinant Covid-19 vaccine.
  • ARS Pharmaceuticals, Inc. SPRY dipped 10.5% to $6.79. ARS Pharmaceuticals recently posted a FY22 loss of $0.87 per share.
  • Ribbon Communications Inc. RBBN dropped 10% to $3.3750.
  • Boxed, Inc. BOXD shares fell 9.8% to $0.2194 after dropping over 29% on Friday.
  • Vigil Neuroscience, Inc. VIGL dropped 9.8% to $11.01. Morgan Stanley maintained Vigil Neuroscience with an Equal-Weight and raised the price target from $12 to $13.
  • Frontier Communications Parent, Inc. FYBR fell 9.1% to $21.42. Frontier partnered with YouTube TV to deliver internet & tv experience. Morgan Stanley downgraded Frontier Communications from Equal-Weight to Underweight and lowered the price target from $23 to $19.
  • Loop Media, Inc. LPTV fell 8.3% to $5.03.
  • PepGen Inc. PEPG dropped 8.1% to $14.00. PopGen recently reported Q4 and full year 2022 financial results.
  • Motorsport Games Inc. MSGM fell 7% to $6.22 after the company posted downbeat results for its fourth quarter on Friday.
  • Pear Therapeutics, Inc. PEAR shares fell 6.7% to $0.2703 after jumping over 15% on Friday.
  • Coinbase Global, Inc. COIN dropped 6.6% to $63.32 after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $86 to $70.

Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasInformation TechnologyInternet Software & ServicesMid-Day MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!